Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer

The majority of previous studies of lobaplatin in small cell lung cancer (SCLC) are small phase I–II studies. The present study aimed to verify the non-inferiority (in terms of efficacy) of lobaplatin plus etoposide (EL) vs. cisplatin plus etoposide (EP) in patients with previously untreated extensi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Lett
Autors principals: Cheng, Ying, Fan, Yun, Liu, Xiaoqing, Liu, Yunpeng, Liu, Jiwei, Wang, Dong, Yu, Yan, Qin, Shukui, Liu, Wei, Huang, Cheng, Zhang, Helong, Liang, Jun, Shi, Jianhua, Sheng, Lijun, Yu, Hao
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2019
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6447897/
https://ncbi.nlm.nih.gov/pubmed/30988825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10125
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars